Can-Fite BioPharma Ltd.

Regulatory Filings • Jul 1, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934

For the Month of June 2025

001-36203 (Commission File Number)

CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)

26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On June 30, 2025, an Annual General Meeting of Shareholders of Can-Fite BioPharma Ltd. (the "Company") approved each of the six proposals brought before the Company's shareholders at the meeting, in accordance with the majority required for each proposal. Each of those proposals was described in the Company's Notice and Proxy Statement with respect to the Company's Annual General Meeting of Shareholders, dated May 16, 2025, attached as Exhibit 99.1 to the Company's Form 6-K that was furnished to the U.S. Securities and Exchange Commission on May 16, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 30, 2025 By: /s/ Motti Farbstein

Motti Farbstein Chief Executive Officer and Chief Financial Officer